From: Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Parameter/day after denosumab injection | Day 0 | Day 0 | 14 | 28 | Day 0 | 14 | 28 | Day 0 | 14 | 28 |
Osteocalcin (age adjusted normal range) [ng/ml] | 24 (10.0-100.0) | 45 (10.0-50.0) | 40 (10.0-50.0) | 21 (9.6-41.0) | ||||||
Parathyroid hormone (12–72 ng/l) | 16 | 7 | 40 | 31 | 14 | 22 | 19 | 48 | 45 | 46 |
Calcium (2.2-2.65 mmol/l) | 2.48 | 2.48 | 2.14 | 2.35 | 2.39 | 2.25 | 2.35 | 2.37 | 2.31 | 2.46 |
25-OH Vitamin D (30–70 μg/l) | 19 | 15.4 | 23.2 | 26.7 | 8.2 | 8.8 | 4.3 | 12.2 | 10.8 | 8.1 |
Desoxypyridinoline/creatinine (age adjusted normal range) [μg/g] | 600 (110-450) | 477 (110-450) | 110 (110-450) | 197 (110-450 | 620 (110-450) | 133 (110-450) | 431* (110-450) | 83 (10-50) | 50 (10-50) | 23 (10-50) |